Literature DB >> 21460065

Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology.

Yoshinori Nishijima1, Arun Sridhar, Ingrid Bonilla, Murugesan Velayutham, Mahmood Khan, Radmila Terentyeva, Chun Li, Periannan Kuppusamy, Terry S Elton, Dmitry Terentyev, Sandor Györke, Jay L Zweier, Arturo J Cardounel, Cynthia A Carnes.   

Abstract

AIMS: Heart failure is a common antecedent to atrial fibrillation; both heart failure and atrial fibrillation are associated with increased myocardial oxidative stress. Chronic canine heart failure reduces atrial action potential duration and atrial refractoriness. We hypothesized that inducible nitric oxide synthase 2 (NOS2) contributes to atrial oxidative stress and electrophysiologic alterations. METHODS AND
RESULTS: A 16-week canine tachypacing model of heart failure was used (n= 21). At 10 weeks, dogs were randomized to either placebo (n = 12) or active treatment (n = 9) with NOS cofactor, tetrahydrobiopterin (BH(4), 50 mg), and NOS substrate (L-arginine, 3 g) twice daily for 6 weeks. A group of matched controls (n = 7) was used for comparison. Heart failure increased atrial NOS2 and reduced atrial BH(4), while L-arginine was unchanged. Treatment reduced inducible atrial fibrillation and normalized the heart failure-induced shortening of the left atrial myocyte action potential duration. Treatment increased atrial [BH(4)] while [L-arginine] was unchanged. Treatment did not improve left ventricular function or dimensions. Heart failure-induced reductions in atrial [BH(4)] resulted in NOS uncoupling, as measured by NO and superoxide anion (O(2)(·-)) production, while BH(4) and L-arginine treatment normalized NO and O(2)(·-). Heart failure resulted in left atrial oxidative stress, which was attenuated by BH(4) and L-arginine treatment.
CONCLUSION: Chronic non-ischaemic heart failure results in atrial oxidative stress and electrophysiologic abnormalities by depletion of BH(4) and uncoupling of NOS2. Modulation of NOS2 activity by repletion of BH(4) may be a safe and effective approach to reduce the frequency of atrial arrhythmias during heart failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460065      PMCID: PMC3112023          DOI: 10.1093/cvr/cvr087

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  56 in total

1.  Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.

Authors:  M J Mihm; F Yu; C A Carnes; P J Reiser; P M McCarthy; D R Van Wagoner; J A Bauer
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

2.  Oral L-arginine in patients with coronary artery disease on medical management.

Authors:  A Blum; L Hathaway; R Mincemoyer; W H Schenke; M Kirby; G Csako; M A Waclawiw; J A Panza; R O Cannon
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

3.  Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation.

Authors:  C A Carnes; M K Chung; T Nakayama; H Nakayama; R S Baliga; S Piao; A Kanderian; S Pavia; R L Hamlin; P M McCarthy; J A Bauer; D R Van Wagoner
Journal:  Circ Res       Date:  2001-09-14       Impact factor: 17.367

4.  P wave duration and risk of longitudinal atrial fibrillation in persons ≥ 60 years old (from the Framingham Heart Study).

Authors:  Jared W Magnani; Victor M Johnson; Lisa M Sullivan; Eiran Z Gorodeski; Renate B Schnabel; Steven A Lubitz; Daniel Levy; Patrick T Ellinor; Emelia J Benjamin
Journal:  Am J Cardiol       Date:  2011-01-20       Impact factor: 2.778

5.  Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function.

Authors:  Arturo J Cardounel; Hongmei Cui; Alexandre Samouilov; Wesley Johnson; Patrick Kearns; Ah-Lim Tsai; Vladomir Berka; Jay L Zweier
Journal:  J Biol Chem       Date:  2006-11-01       Impact factor: 5.157

6.  Duration of heart failure and the risk of atrial fibrillation: different mechanisms at different times?

Authors:  Andrew C Rankin; Antony J Workman
Journal:  Cardiovasc Res       Date:  2009-08-27       Impact factor: 10.787

7.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

8.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension.

Authors:  Ulf Landmesser; Sergey Dikalov; S Russ Price; Louise McCann; Tohru Fukai; Steven M Holland; William E Mitch; David G Harrison
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion.

Authors:  Wei Xia; Zuomin Yin; Jingjie Li; Ying Song; Xiufen Qu
Journal:  Pacing Clin Electrophysiol       Date:  2009-09-30       Impact factor: 1.976

Review 10.  Electrical, contractile and structural remodeling during atrial fibrillation.

Authors:  Maurits Allessie; Jannie Ausma; Ulrich Schotten
Journal:  Cardiovasc Res       Date:  2002-05       Impact factor: 10.787

View more
  35 in total

1.  Differential regulation of EHD3 in human and mammalian heart failure.

Authors:  Hjalti Gudmundsson; Jerry Curran; Farshid Kashef; Jedidiah S Snyder; Sakima A Smith; Pedro Vargas-Pinto; Ingrid M Bonilla; Robert M Weiss; Mark E Anderson; Philip Binkley; Robert B Felder; Cynthia A Carnes; Hamid Band; Thomas J Hund; Peter J Mohler
Journal:  J Mol Cell Cardiol       Date:  2012-03-03       Impact factor: 5.000

2.  HPLC analysis of tetrahydrobiopterin and its pteridine derivatives using sequential electrochemical and fluorimetric detection: application to tetrahydrobiopterin autoxidation and chemical oxidation.

Authors:  Roberto Biondi; Giuseppe Ambrosio; Francesco De Pascali; Isabella Tritto; Enrico Capodicasa; Lawrence J Druhan; Craig Hemann; Jay L Zweier
Journal:  Arch Biochem Biophys       Date:  2012-01-20       Impact factor: 4.013

3.  Prognostic value of leucine/phenylalanine ratio as an amino acid profile of heart failure.

Authors:  Hiroaki Hiraiwa; Takahiro Okumura; Toru Kondo; Toshiaki Kato; Shingo Kazama; Yuki Kimura; Toshikazu Ishihara; Etsuo Iwata; Masafumi Shimojo; Sayano Kondo; Soichiro Aoki; Yasunori Kanzaki; Daisuke Tanimura; Hiroaki Sano; Yoshifumi Awaji; Sumio Yamada; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2021-01-22       Impact factor: 2.037

Review 4.  Nitric oxide signalling in cardiovascular health and disease.

Authors:  Charlotte Farah; Lauriane Y M Michel; Jean-Luc Balligand
Journal:  Nat Rev Cardiol       Date:  2018-02-01       Impact factor: 32.419

5.  The 894G Allele of the Endothelial Nitric Oxide Synthase 3 (eNOS) is Associated with Atrial Fibrillation in Chronic Systolic Heart Failure.

Authors:  Fuad Fares; Yoav Smith; Naiel Azzam; Barak Zafrir; Basil S Lewis; Offer Amir
Journal:  J Atr Fibrillation       Date:  2012-12-16

6.  Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu.

Authors:  Nathan E K Procter; Jocasta Ball; Doan T M Ngo; Yuliy Y Chirkov; Jeffrey S Isenberg; Elaine M Hylek; Simon Stewart; John D Horowitz
Journal:  Herz       Date:  2015-07-02       Impact factor: 1.443

7.  Increased p-cresyl sulfate level is independently associated with poor outcomes in patients with heart failure.

Authors:  Chao-Hung Wang; Mei-Ling Cheng; Min-Hui Liu; Ming-Shi Shiao; Kuang-Hung Hsu; Yu-Yen Huang; Cheng-Cheng Lin; Jui-Fen Lin
Journal:  Heart Vessels       Date:  2015-07-02       Impact factor: 2.037

Review 8.  Antioxidant therapies for the management of atrial fibrillation.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Guangping Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 9.  Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update.

Authors:  Alejandra Gutierrez; David R Van Wagoner
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

10.  Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Authors:  Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.